CJC-1295 (no DAC)
Mod GRF 1-29 / Modified GRF
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
Wirkmechanismus
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
Forschungsprotokolle
Nur für Forschungszwecke. Keine medizinische Beratung.
Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection, typically combined with a GHRP (ipamorelin, GHRP-2, or GHRP-6). Administer on empty stomach 30 min before or 2 hours after meals.
Forschungsnotizen
Clinical Research Status
CJC-1295 without DAC has been studied in clinical trials demonstrating dose-dependent increases in GH and IGF-1 levels. The no-DAC version has a short half-life of approximately 30 minutes, requiring more frequent dosing but producing GH pulses rather than sustained elevation. No FDA approval exists for any indication; it remains an investigational compound available through research suppliers.
Key Published Findings
Clinical studies show that Modified GRF(1-29) increases GH secretion 2-10 fold when administered subcutaneously. Combination with GHRPs produces synergistic effects, with GH output greater than either compound alone. Research demonstrates improvements in body composition, sleep quality, and recovery markers in study participants over 4-12 week protocols.
Safety Profile
Side effects are generally mild and include transient flushing, headache, dizziness, and injection site reactions. Unlike exogenous GH, it preserves the hypothalamic-pituitary feedback loop, reducing risk of GH excess. Water retention and joint stiffness may occur at higher doses, consistent with elevated IGF-1 levels.
Drug Interactions & Contraindications
Should not be combined with somatostatin analogs (e.g., octreotide) which directly oppose its mechanism. Caution advised with glucocorticoids which suppress the GH axis. Contraindicated in individuals with active malignancy due to IGF-1's proliferative effects on certain cancer types.
Comparison to Related Compounds
The no-DAC version produces a short GH pulse (~30 min half-life) versus CJC-1295 with DAC which elevates GH for 6-8 days due to albumin binding. Most practitioners prefer no-DAC for its more physiological pulsatile pattern and lower risk of prolonged IGF-1 elevation. Sermorelin is an older, less potent GHRH analog that CJC-1295 has largely replaced in research settings.
Community Observations
Typically dosed at 100-300mcg subcutaneously 1-3 times daily, most commonly before bed and upon waking. The combination of Mod GRF + Ipamorelin at 100mcg each is considered the standard research protocol for GH optimization. Users report improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 month protocols.
Halbwertszeit
~30 minutes
Rekonstitution
Bacteriostatic water (BAC)
Lagerung
Lyophilisiert
Refrigerate 2-8C up to 18 months.
Rekonstituierter
Refrigerate 2-8C. Use within 14 days.
Rechtsstatus USA
Auch bekannt als
Häufig gestellte Fragen
Was ist CJC-1295 (no DAC)?
CJC-1295 (without DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) consisting of amino acids 1-29 of GHRH with amino acid substitutions to increase stability and receptor binding affinity. Also known as Modified GRF(1-29) or Mod GRF, it produces pulsatile growth hormone release that more closely mimics natural physiology compared to the DAC variant. It is most commonly combined with a GHRP such as Ipamorelin to amplify GH output through dual-pathway stimulation.
Wie wirkt CJC-1295 (no DAC)?
Modified growth hormone releasing hormone (GHRH) analog with amino acid substitutions at positions 2, 8, 15, and 27 to prevent enzymatic degradation. Stimulates pituitary GHRH receptors to amplify natural GH pulses without extending the pulse duration.
Wie ist der regulatorische Status von CJC-1295 (no DAC) in den USA?
Research chemical (not FDA-approved)
Wie lang ist die Halbwertszeit von CJC-1295 (no DAC)?
~30 minutes
Wie wird CJC-1295 (no DAC) noch genannt?
Mod GRF 1-29, Modified GRF
Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.
Ganze Erklärung lesen